SPY is an exchange-traded fund (ETF) that aims to replicate the performance of the S&P 500 Index. The S&P 500 Index includes 500 of the largest publicly traded companies in the United States, representing a broad cross-section of the U.S. economy.
Metrics and analysis →BIIB
Biogen specializes in the development of therapies for neurological diseases, including multiple sclerosis and Alzheimer’s.
- Open
- 247.82
- High
- 253.00
- Low
- 247.82
- Prev close
- 247.13
- Volume
- 1M
- Avg vol 10
- 1M
Today · Market closed · opens Mon 9:30 AM
BIIB chart
Scroll or pinch to zoom, drag to pan, or use the buttons on the chart. About the price history
Technical analysis
Daily bars · last bar Nov 20, 2026 · close 249.28
Leaning buy. 6 of 18 signals point up against 3 down, carried by trend and volume. Momentum is mostly neutral. Volatility is mostly neutral. Stoch RSI sits in oversold territory.
Trend
Momentum
Volatility
Volume
Leaning buy. The close is above 15 of 24 averages and below 9. Price is below the short-term averages (5 to 20) and above the long-term ones (50 to 200). SMA 50 is above SMA 200 (236.82 vs 206.87).
| Period | SMA | EMA | WMA | WEMA |
|---|---|---|---|---|
| 5 | 250.05 | 249.81 | 249.49 | 250.23 |
| 10 | 251.57 | 250.21 | 250.62 | 248.60 |
| 20 | 250.63 | 248.32 | 250.71 | 242.22 |
| 50 | 236.82 | 238.86 | 243.82 | 226.88 |
| 100 | 223.15 | 226.64 | 232.51 | 210.00 |
| 200 | 206.87 | 208.62 | 217.89 | 191.90 |
Green: the close is above that average. Red: below it.
From the bar before the last one. Nearest classic support is the pivot at 247.60. Nearest resistance is R1 at 251.62.
| Level | Classic | Fibonacci | Camarilla | Floor | Woodie | DeMark |
|---|---|---|---|---|---|---|
| R3 | 264.62 | 256.11 | 249.47 | 260.13 | 261.51 | — |
| R2 | 256.11 | 252.86 | 248.69 | 256.11 | 256.80 | — |
| R1 | 251.62 | 250.85 | 247.91 | 251.62 | 253.00 | 249.61 |
| Pivot | 247.60 | 247.60 | 247.60 | 247.60 | 248.29 | 246.60 |
| S1 | 243.11 | 244.35 | 246.35 | 243.11 | 244.49 | 241.10 |
| S2 | 239.09 | 242.34 | 245.57 | 239.09 | 239.78 | — |
| S3 | 230.58 | 239.09 | 244.79 | 234.60 | 235.98 | — |
Patterns that formed on the last 5 bars, newest first.
A small body with shadows longer than the body on both sides.
Neither side won the bar. On its own it says little; after a strong move it warns the move is tiring.
A candle with a short body and short shadows: a quiet bar.
A small gain on little range; weak on its own.
A small body at the bottom of the candle with a long upper shadow, after a decline.
Buyers tested higher prices; a turn up may follow, best confirmed by the next candle.
A candle with a short body and short shadows: a quiet bar.
A small loss on little range; weak on its own.
How candlestick references usually rate the pattern. It is not a success rate measured on this ticker. About candle patterns
| Date | Open | High | Low | Close | Volume | Change |
|---|---|---|---|---|---|---|
| Nov 20, 2026 | 248.74 | 253.00 | 248.04 | 249.28 | 1M | +0.54 |
| Nov 19, 2026 | 251.26 | 252.09 | 243.58 | 247.13 | 1M | −4.13 |
| Nov 18, 2026 | 247.78 | 252.79 | 247.00 | 251.41 | 1M | +3.63 |
| Nov 17, 2026 | 248.97 | 252.72 | 248.27 | 250.79 | 969K | +1.82 |
| Nov 16, 2026 | 255.25 | 255.42 | 250.65 | 251.65 | 840K | −3.60 |
| Nov 13, 2026 | 250.58 | 255.04 | 249.52 | 253.40 | 1M | +2.82 |
| Nov 12, 2026 | 255.00 | 255.05 | 250.43 | 250.48 | 793K | −4.52 |
| Nov 11, 2026 | 249.78 | 255.19 | 249.44 | 253.40 | 1M | +3.62 |
| Nov 10, 2026 | 253.56 | 254.70 | 250.44 | 253.25 | 735K | −0.31 |
| Nov 9, 2026 | 250.36 | 261.00 | 246.44 | 254.87 | 1M | +4.51 |
| Nov 6, 2026 | 241.28 | 250.03 | 240.00 | 248.35 | 1M | +7.07 |
| Nov 5, 2026 | 255.25 | 255.70 | 243.65 | 243.93 | 1M | −11.32 |
| Nov 4, 2026 | 253.54 | 255.35 | 246.49 | 254.46 | 1M | +0.92 |
| Nov 3, 2026 | 247.32 | 253.14 | 246.25 | 248.93 | 1M | +1.61 |
| Nov 2, 2026 | 253.81 | 255.53 | 247.91 | 249.01 | 1M | −4.80 |
| Oct 30, 2026 | 255.39 | 258.73 | 251.19 | 253.62 | 1M | −1.77 |
| Oct 29, 2026 | 250.15 | 255.55 | 246.48 | 249.65 | 1M | −0.50 |
| Oct 28, 2026 | 244.93 | 258.78 | 243.03 | 244.05 | 2M | −0.88 |
| Oct 27, 2026 | 250.35 | 253.98 | 248.46 | 252.73 | 1M | +2.38 |
| Oct 26, 2026 | 251.02 | 254.11 | 249.61 | 252.26 | 959K | +1.24 |
| Oct 23, 2026 | 251.68 | 252.44 | 246.15 | 250.69 | 1M | −0.99 |
| Oct 22, 2026 | 240.61 | 254.41 | 240.02 | 253.84 | 2M | +13.23 |
| Oct 21, 2026 | 242.02 | 243.32 | 240.13 | 240.98 | 813K | −1.04 |
| Oct 20, 2026 | 236.79 | 244.65 | 235.96 | 243.10 | 1M | +6.31 |
| Oct 19, 2026 | 231.81 | 236.00 | 231.04 | 233.48 | 950K | +1.67 |
| Oct 16, 2026 | 235.75 | 236.87 | 232.36 | 232.65 | 1M | −3.10 |
| Oct 15, 2026 | 236.46 | 240.99 | 235.22 | 235.35 | 2M | −1.11 |
| Oct 14, 2026 | 228.99 | 234.20 | 228.00 | 232.83 | 2M | +3.84 |
| Oct 13, 2026 | 230.34 | 231.04 | 226.71 | 228.90 | 1M | −1.44 |
| Oct 12, 2026 | 233.98 | 238.24 | 229.00 | 229.41 | 1M | −4.57 |
Performance
Daily returns for Jan 1, 2026 – Nov 22, 2026 (YTD). About the returns · About the risk figures
1 month return
-1.67%
Change in value over the past month.
3 month return
14.43%
Change in value over the last three months.
Max drawdown
14.34%
Largest fall from a peak to the low that followed.
Standard deviation
35.18%
How far daily returns stray from their average, annualised.
Sharpe ratio
1.26
Return above the risk-free rate per unit of volatility.
Calmar ratio
3.09
Annualised return against the maximum drawdown.
BIIB summary
Loading summary…
BIIB, answered
What are the challenges Biogen faces in the market?
Biogen faces challenges such as competition from other pharmaceutical companies and regulatory hurdles in drug approval processes.
How does Biogen approach drug development?
Biogen employs a rigorous approach, utilizing clinical trials and research to ensure safety and efficacy before launching new treatments.
What role does innovation play in Biogen’s strategy?
Innovation is central to Biogen’s strategy, focusing on developing new therapies to address unmet medical needs in neurology.
What are some key products from Biogen?
Key products include Tecfidera, Avonex, and Spinraza, which are used for various neurological conditions.
How can investors track Biogen’s performance?
Investors can track Biogen’s performance through financial news platforms, stock market apps, and Biogen’s investor relations page.
What recent developments has Biogen announced?
Recent developments include new clinical trial results and potential product launches; for the latest updates, check their press releases.
Is Biogen involved in any partnerships?
Yes, Biogen often collaborates with academic institutions and other companies for research and development purposes.
What is the impact of clinical trial results on Biogen?
Positive clinical trial results can lead to stock price increases and greater market confidence in Biogen’s products.
How can I invest in Biogen?
You can invest in Biogen by purchasing shares through a brokerage account or investing in funds that include Biogen in their portfolio.
How does Biogen research impact the healthcare industry?
Biogen’s research contributes to advancements in treating complex neurological disorders, impacting patient care and treatment options.
BIIB in the news
Top market assets
Discover our curated selection of top-performing exchange-traded funds (ETFs) that represent a diverse range of investment opportunities.
QQQ is an exchange-traded fund (ETF) that tracks the performance of the Nasdaq-100 Index. This index includes 100 of the largest non-financial companies listed on the Nasdaq Stock Market, primarily focusing on technology and innovation sectors.
Metrics and analysis →DIA is an exchange-traded fund (ETF) that aims to track the performance of the Dow Jones Industrial Average (DJIA). The DJIA is a stock market index consisting of 30 large, publicly traded companies in the United States, representing a broad range of industries.
Metrics and analysis →IWM is an exchange-traded fund (ETF) that seeks to track the performance of the Russell 2000 Index. The Russell 2000 Index measures the performance of the 2,000 smallest stocks in the Russell 3000 Index, representing a broad segment of small-cap U.S. companies.
Metrics and analysis →Enhance Your BIIB Trading Now
Maximize your trading efficiency with ohlcx.com. Our advanced trading system provides detailed insights and actionable strategies for BIIB. Don’t wait—Boost your investment success with us and see how our platform can help you achieve your trading goals!
Disclaimers
The information displayed on this site is sourced from third-party providers and is believed to be reliable. OHLCX has not independently verified this data and does not guarantee its accuracy. Content is for educational and informational purposes only and is not financial or investment advice.
With any investment, your capital is at risk. Past performance is no guarantee of future results. Consult your provider's terms and privacy policies where applicable.
Prices, charts and every figure derived from them are delayed by at least 15 minutes and are provided for information only; we do not guarantee their accuracy or timeliness.
Securities products are: Not FDIC insured · Not bank guaranteed · May lose value
Trademarks and logos are the property of their respective owners and do not represent endorsements of any kind.